RecruitingNCT04134923

Imaging Biomarkers in Preclinical and Symptomatic AD

Imaging Biomarkers in Preclinical and Symptomatic AD. (ACS PiB IND)


Sponsor

Tammie L. S. Benzinger, MD, PhD

Enrollment

375 participants

Start Date

Jun 8, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this research study is to evaluate adult children of parents with and without Alzheimer's disease which represent an ideal population for investigating the biological changes that precede the clinical onset of AD. The investigators will be imaging the brain to detect the presence of amyloid deposits (plaques in the brain). Amyloid is a protein that may be related to dementia of Alzheimer's disease (DAT).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using brain imaging (including PET and MRI scans) to look for early biological markers of Alzheimer's disease before symptoms appear, in people who are part of an established Alzheimer's disease research center at Washington University. **You may be eligible if...** - You are 18 or older, any race or gender - You are currently enrolled in the Knight Alzheimer's Disease Research Center at Washington University **You may NOT be eligible if...** - You have a sensitivity or allergy to the imaging agent used (PIB) - You have a pacemaker, metal implants, severe claustrophobia, or another reason you cannot safely have MRI or PET scans - You are pregnant or breastfeeding - You have participated in radioactive research studies recently enough that additional radiation would exceed safe limits - You are currently in another clinical trial involving an active study drug Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[11C] Pittsburgh Compound-B (PIB)

Participants will receive a single intravenous bolus injection of 6.0 - 20.0 mCi (222-740 MBq) of the investigational radiotracer \[11C\] PIB. Participants will then undergo a \[11C\] PIB PET/CT scan conducted in the Center for Clinical Imaging Research (CCIR) facility.


Locations(1)

Washington University School of Medicine

St Louis, Missouri, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04134923


Related Trials